WINTON GROUP Ltd grew its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 23.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,530 shares of the medical research company’s stock after purchasing an additional 4,866 shares during the quarter. WINTON GROUP Ltd’s holdings in NeoGenomics were worth $392,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cornerstone Wealth Management LLC acquired a new position in shares of NeoGenomics in the 2nd quarter valued at about $528,000. Hussman Strategic Advisors Inc. acquired a new position in shares of NeoGenomics in the 2nd quarter valued at about $1,966,000. Emerald Advisers Inc. PA lifted its stake in shares of NeoGenomics by 8.6% in the 2nd quarter. Emerald Advisers Inc. PA now owns 1,374,446 shares of the medical research company’s stock valued at $18,019,000 after purchasing an additional 108,899 shares during the period. Emerald Mutual Fund Advisers Trust lifted its stake in shares of NeoGenomics by 57.1% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 443,806 shares of the medical research company’s stock valued at $5,818,000 after purchasing an additional 161,300 shares during the period. Finally, Jennison Associates LLC lifted its stake in shares of NeoGenomics by 18.7% in the 2nd quarter. Jennison Associates LLC now owns 43,736 shares of the medical research company’s stock valued at $573,000 after purchasing an additional 6,888 shares during the period. Institutional investors and hedge funds own 80.28% of the company’s stock.

A number of research firms recently weighed in on NEO. Benchmark set a $22.00 price target on NeoGenomics and gave the stock a “buy” rating in a research note on Thursday, November 1st. Craig Hallum upped their price target on NeoGenomics from $17.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, October 31st. Raymond James upped their price target on NeoGenomics from $16.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, October 31st. Zacks Investment Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating and set a $21.00 price target on the stock in a research note on Saturday, November 3rd. Finally, BidaskClub downgraded NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $20.08.

Shares of NeoGenomics stock opened at $15.60 on Wednesday. The company has a market capitalization of $1.50 billion, a PE ratio of 260.00 and a beta of -0.01. NeoGenomics, Inc. has a 52 week low of $7.08 and a 52 week high of $19.04. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.13 and a quick ratio of 3.98.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, October 30th. The medical research company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. The firm had revenue of $69.10 million during the quarter, compared to the consensus estimate of $66.13 million. NeoGenomics had a return on equity of 2.63% and a net margin of 1.70%. The company’s quarterly revenue was up 16.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.01 earnings per share. On average, equities research analysts predict that NeoGenomics, Inc. will post 0.11 earnings per share for the current fiscal year.

In other news, insider Robert J. Shovlin sold 216,493 shares of the stock in a transaction that occurred on Monday, November 12th. The stock was sold at an average price of $17.00, for a total value of $3,680,381.00. Following the completion of the sale, the insider now directly owns 339,884 shares of the company’s stock, valued at $5,778,028. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Lynn A. Tetrault sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 14th. The shares were sold at an average price of $16.16, for a total value of $80,800.00. Following the completion of the transaction, the director now directly owns 47,346 shares of the company’s stock, valued at $765,111.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 4,981,643 shares of company stock valued at $83,563,998. Company insiders own 12.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dailypolitical.com/2018/11/21/neogenomics-inc-neo-shares-bought-by-winton-group-ltd.html.

NeoGenomics Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Further Reading: Investing strategies using the yield curve

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.